ALS Canada’s work is empowered by community. Discover how, in 2023, our efforts to support the ALS community ensured that people affected by ALS received the highest standard of care possible, and helped loved ones pursue their education goals.
It takes a community: Supporting people with ALS
Living with ALS can have many challenges, but with the support of the community, people living with the disease can navigate their journey with greater ease. ALS Canada’s Community Leads (CLs) in Ontario play an important role by offering individualized support to people diagnosed with ALS and their circle of support, which can include family members and health care professionals.
“Our support is individualized from person to person based on the progression of the disease, symptoms, and resources and supports are available in their community,” says Kim Barry, Vice-President of Community Services at ALS Canada. “There’s no waitlist; when someone is diagnosed, they are referred to our Community Leads, who are specialized in supporting someone living with ALS. They are there to help answer questions, support symptom management, and evaluate and facilitate the medical equipment needed now and in the future.”
ALS affects more than the person living with the disease. It’s common for a spouse or child to take on the role of primary caregiver, who will also have questions of their own about how to best assist their family member. In addition to providing information and resources to the caregiver, it’s not uncommon for a CL to support at least six additional people within a person’s care network who will have a role to aid in some way.
Navigating ALS becomes significantly less daunting for people affected by the disease, especially when they have access to someone who has been through the journey. This proactive approach not only offers a lifeline but also opens up an opportunity to maintain an important level of quality of life, safety, and independence, bringing a sense of relief and comfort.
“Although an ALS diagnosis can be devastating, it’s important to know that there is still life to enjoy,” says Kim. An example Kim shares of a recent client experience, “When John was diagnosed, that same day we were connected and scheduled a time to meet with him to discuss his initial questions. In the following weeks, the Community Lead worked closely with him and his wife to determine the care they wanted and when they wanted it. ALS is different for everyone; each day can bring a new complexity that can be easily managed with support, whether transitioning to a new mobility device, assistance with paperwork for transportation, or a referral to an allied health professional in the community. Ultimately, it’s about providing help and support, so the family can stay together at home.”
Giving back for a brighter future: recognizing resilience with the ALS Canada Kevin Daly Bursary
No one better understands the adversities while navigating a loved one’s ALS diagnosis than the ALS community themselves. The profound impact of the disease creates hurdles when thinking about achieving goals and aspirations created prior to a diagnosis. Life with ALS is different for everyone, but the mark it makes on each person drives a sense of compassion and desire to support others in the community.
In 2023, in partnership with the friends and colleagues of ALS community member Kevin Daly, ALS Canada sought to support young people navigating the impact of ALS. In celebration of Kevin, the ALS Canada Kevin Daly Bursary was created – inspired by his courage and dedication to other ALS families. The $2,500 bursary is awarded annually to post-secondary students across Canada whose lives have been touched by ALS. “Empowering students affected by ALS with this bursary not only eases their financial burdens but also sends a powerful message of a community connected and an understanding of the realities children face when a family has been impacted by ALS,” says Tammy Moore, CEO, ALS Canada.
The 2023 ALS Canada Kevin Daly Bursary was awarded to three students across Canada – Catherine Brassard, Daniella D’Amici, and Sarah Jacob – providing dual-purpose support through financial relief and community connection. “Day to day, it can be stressful, so having an external form of security makes a huge difference to me,” says D’Amici. “As well as connecting with the ALS Canada team and having them understand what I’m experiencing – that has added a sense of community that has been really special.”
“Receiving this bursary represents a source of comfort in a particularly difficult period, as it eases an emotional and financial burden. Having proof that my difficulties are recognized and supported encourages me to cultivate my resilience,” Brassard says. Supporting young adults navigating not only their goals for further education but also the harsh reality of ALS is critical to the future of ALS. ALS Canada and the Daly family congratulate the 2023 recipients for their resilience and academic dedication and look forward to supporting more students in the years to come.
Learn more about our work in 2023 by exploring our latest annual report.
ALS Canada’s work is empowered by community. Discover how, in 2023, our work within the ALS community helped people affected by the disease feel empowered and informed to make decisions and engage in advocacy efforts.
Empowering advocacy with the ALS Canada Canadian ALS Learning Institute
The landscape of ALS research is ever-changing as researchers continue to make developments. However, research is just half of the journey – ensuring effective treatments are understood and accessible is critical to supporting Canadians living with ALS, and nobody understands this better than those affected by the disease right now.
ALS Canada seeks to empower Canadians affected by ALS with the right knowledge, tools, and support to navigate its current realities and advocate effectively for change. That’s why the Canadian ALS Learning Institute (CALI) was created – a small-group learning experience for people affected by the disease to better understand the Canadian ALS landscape, clinical research, therapy development, and how to advocate effectively.
Since the CALI launched in 2021, graduates of the program who become ALS Canada Community Ambassadors, have shown power in their advocacy efforts, actively putting their learnings into action. Jennifer Hutton, graduate of the 2022 CALI cohort, jumped into advocacy straight away following her husband’s ALS diagnosis in 2021. “I had the power and passion to advocate but I felt that I lacked the knowledge needed to fully put myself out there,” said Hutton, leading her to reach out to ALS Canada and discovering the CALI.
“The CALI outlined the current state of ALS from all avenues including gaps in healthcare, research, drug development and support. I’ve been able to use that knowledge when speaking with and advocating on a much broader scale than just my personal story.” Since graduating from the CALI and becoming an ALS Canada Community Ambassador, Jennifer has been able to engage various government officials in her home province, including Nova Scotia’s Premier and provincial health minister, as well as create a relationship and consistent dialogue with the Ministry of Health and Wellness support staff.
“[Participating in the CALI] you gain an entire community of people that will help support you and mentor you through your journey in not only advocacy, but ALS in general,” says Hutton. As she continues forward on her own advocacy journey, backed by the CALI community, she leaves some words of advice for anyone affected by ALS interested in beginning theirs, “Be patient. It’s not easy, but it’s worth it. Lean on the community for support and keep going.”
Learn more about our work in 2023 by exploring our latest annual report.
Walk, ride, or pull – no challenge is too big when it comes to supporting a world free of ALS. Year round, ALS Canada events bring together the community, demonstrating your commitment to raising awareness, honouring the people we’ve loved and lost, and ultimately helping change the future of ALS.
Creating change with community: ALS Canada 2023 events
For everything that ALS takes, the connection of a community is one thing it can’t. Each year, we are reminded of the strength, commitment, and impact the ALS community has as we come together.
We’ve said it before – our events are more than just fundraisers; they are a true demonstration of a commitment to changing what it means to live with ALS. From local communities to the greater ALS community, hundreds of people rally together for change at our annual events.
In 2023, the power of community was hard to ignore. For Tony Mongillo, who lost his father, Joe, to ALS in 2010, participating in the ALS Canada Pull to End ALS is a chance to bring together family and friends. Mongillo’s team, “No Ordinary Joes”, is a large and energetic force at the event passionately showing their support for people living with ALS and their families. Jumping in as extra pushing power when opposing teams need a little help – Tony and his team made it very clear: community support creates change.
It’s hard to deny the feeling of unity in the face of adversity as we come together – a feeling that can resonate more than the impact of funds raised. “So many others across Canada need the same level of support and care we received. It’s critical that we come together as a community to fund ALS Canada’s essential services, and ALS research that could one day find a cure,” says Michael Petrachenko, who lost his wife, Monique, to ALS in 2022. After years of participating in the ALS Canada Walk to End ALS with Monique by his side, at the 2023 Walk to End ALS, Michael continues to lead “Team Unique Monique”, sure that she’d be so happy to see them raising money and awareness in her honour.
A new face at the 2023 ALS Canada Revolution Ride, Matthew Horowitz showcased the impact getting into gear, with the support of community, creates. Though not a big cyclist himself, Matthew and his team “Big Mike and the Boys” rallied together for change after his father, Michael*, was diagnosed with ALS in January 2022 (*Michael Horowitz passed away May 2024). The team raised a staggering $110,659 – Matthew himself raising more than $104,000 of that total – to help people living with ALS and their families just like his.
Together, we can achieve more. The presence of a community connected is strong at ALS Canada events across Canada – a potent reminder that as a community we are creating change, raising awareness, and working a world free of ALS.
Teaming up to take our shot with the ALS Canada Buck-A-Puck for ALS
Shifting from making a shot on the opposing net to taking a stand against ALS was an easy choice for three young hockey players from Etobicoke.
In September 2021, Steve Daly – coach for the Humber Valley Sharks U12 A hockey team – was diagnosed with ALS. Although disease progression persisted, Steve never backed down from being a strong coach and embodying the values of perseverance and determination he encouraged in his players. After losing their coach to this relentless disease in January 2022 the Humber Valley Sharks vowed to make ALS history. Before everyone knew it, Buck-A-Puck for ALS was born with a concept simple yet powerful: raise a buck, shoot a puck.
Buck-A-Puck for ALS began as a community event with The Stevie Fever for ALS Foundation, to honour Coach Steve, organized by Sarah Lopez and Heather Evans, along with Joshua Lopez, Liam Muffitt, and George Daly of the Humber Valley Sharks. “Buck-A-Puck for ALS was a way to channel all the emotion experienced as Steve was challenged by the disease – to show the kids that there is always a way to help, even if it seems like there is nothing you can do,” Heather explains.
After just the first year, the team had raised more than $90,000 within a small Etobicoke community – a true testament to the power of coming together. “What we’ve already accomplished through Buck-A-Puck speaks to what can happen in the future – there is a lot of potential with what it can achieve to make a change,” Liam says. To take their grassroots fundraiser to the next level, the team partnered with ALS Canada in 2023 evolving to a nation-wide initiative as the ALS Canada Buck-A-Puck for ALS.
With support from hockey players and fans across Canada, taking their shot at the net to change what it means to live with ALS, Buck-A-Puck for ALS got one step closer to the ultimate goal of $1 million raised for ALS research. In 2023, thanks to a passionate hockey community and a shared commitment to creating a world free of ALS, Buck-A-Puck for ALS raised $60,000 and counting! ALS Canada is excited to continue to work alongside the Buck-A-Puck organizers – fostering the growth of this passionate initiative, uniting a love for hockey with the desire to make a difference to create a lasting impact in the fight against this debilitating disease.
Evoking change through connection
The impact of an ALS diagnosis is unrelenting. Navigating a reality no one chooses but is forced to face, the accompanying challenges can feel isolating.
At ALS Canada, we believe in the power of storytelling. Creating the space to share lived experiences and invite conversation to generate real impact. Impact in fostering a sense of connection to remind you that you are not alone while navigating ALS and educating others about the realities of living with the disease, inspiring them to get involved. In 2023, we shared the stories of our communities, highlighting the realities of living with the disease and the urgent need for change during for our “While I still can…” campaign.
ALS community members who shared their stories in 2023, including Mehboob (left), Chris, and Sandra
Community members Mehboob, Sandra, and Chris shared their experiences of their lives changed by ALS. Honest, direct displays of the impact of this devastating disease not only creating awareness, but also illustrating that we’re in this together. In the midst of raising funds for a world free of ALS during Giving Tuesday and the holiday season, our community raised their voices on social media in response to the experiences shared. Offering words of support, reflection, and hope – uniting us.
During our “While I still can…” campaign, we witnessed, as Mehboob explains, “what collective compassion and commitment can achieve.” The stories of lived experience and the truth of what people living with ALS and their families are going through drove involvement and commitment for a difference raising more than $605,000 in generous donations. A testament to the power of storytelling, our truths, and that we are not alone – there is a community right here.
Learn more about our work in 2023 by exploring our latest annual report.
ALS Canada’s work is empowered by community. Discover how, in 2023, our collaboration with clinicians and investments in research aims to enhance care and the potential for future treatments.
CALS Research Network: Connecting Canada’s clinicians and researchers
As a national convenor of the ALS community, ALS Canada was proud to provide the foundational funding to establish the Canadian ALS Research Network (CALS) in 2008. The network was established to formally unite clinician researchers and to demonstrate to the pharmaceutical industry the benefits of bringing clinical trials to the country.
Recognizing the significance and effectiveness of CALS in uniting clinicians in Canada to accelerate research and improve care for people affected by ALS and their families, ALS Canada assumed administrative management of the network in 2017.
“CALS informs all areas of our mission as a trusted source the ALS community can rely on,” says Colleen Doyle, Senior Manager of Research and CALS at ALS Canada. “These are the experts doing the work in our communities, whether in a clinical setting or within the lab, working to advance what we know about the disease and potential treatments.”
Over the past five years, CALS has grown significantly, doubling its membership and extending its reach across Canada. This growth has strengthened its ability to collaborate effectively as a network, providing opportunities to mentor early career clinicians, partner more closely with pharmaceutical companies to bring promising clinical trials to Canada, and support grassroots research efforts led by physicians. Since its inception, more than 35 ALS clinical trials have taken place at CALS centres across the country.
These efforts have helped develop resources to assist people living with ALS, clinicians, and allied health professionals. This includes ReferALS, designed to help general neurologists recognize ALS symptoms earlier and refer potential cases to a CALS clinic. By speeding up the diagnosis process, ReferALS ensures quicker access to vital care, approved treatments, and the possibility of participating in clinical trials, all of which can make a significant difference in slowing down the progression of the disease and enhancing the quality of life.
In 2023, ALS Canada surveyed CALS members to gain insights into their communities’ support and healthcare services. Thanks to the collaborative nature of its membership, the survey had a high response rate and will help identify gaps and barriers faced by people living with ALS. With this valuable data, ALS Canada and our partners are better equipped to advocate government for improvements and ensure equitable access to care for everyone affected by ALS.
Drawn to the mysteries of ALS research
It was the mystery surrounding the disease that drew Dr. Alex Parker to ALS research. Since his grad school days, he has had a deep interest in neurodegenerative diseases, their onset, progression of symptoms, and their variation between each person diagnosed.
To help solve this mystery, Dr. Parker’s team at the Department of Neuroscience at the Centre de recherche du CHUM at Université de Montréal is investigating the microbiome, a natural collection of bacteria and other microbes that play a crucial role in maintaining our health, including possibly our brain and spinal cord. The team has developed simple ALS models using worms to better understand how motor neurons degenerate and explore whether
Thanks to the support of the ALS Canada Research Program, in partnership with Brain Canada, the team has made significant progress in its research. Investigating the effects of probiotics has the potential to lead to new ALS therapies, and this area of study has successfully led to clinical trials for other diseases. In Dr. Parker’s lab, certain probiotics have been found to be protective in the ALS models, one of which will be tested in an upcoming clinical trial. These trials could provide promising new clues to unlocking the mysteries of this terrible disease.
“Although I spend most of my time in the lab, I know that figuring out ALS is more than an academic exercise. It is a race against time for people living with the disease,” says Dr. Parker. “The speed at which ALS progresses can be fast, and it’s almost always devastating, so I appreciate that the ALS community needs answers as soon as possible.”
Learn more about our work in 2023 by exploring our latest annual report.
In early March, members of the ALS community joined ALS Canada in Ottawa for two days of advocacy training and meetings with politicians and other government officials. From people living with ALS and their caregivers and family members to researchers, clinicians and volunteers, our delegation of 35 people made the following asks of the federal government: make substantial changes to the drug access pathway that will enable equitable, timely and affordable access to ALS therapies; and provide funding for dedicated ALS research to contribute to the development of those therapies. More specifically:
Follow through on drug access commitments, including expediting the creation of the Canadian Drug Agency so that the timeline for drug approvals and reimbursement decisions is shortened.
Include people with lived experience in the decision-making process.
Fund dedicated ALS research by supporting CAPTURE ALS, a Canadian-led open science platform of comprehensive biological data from 1,000 Canadians living with ALS that will enable the study of why ALS progresses differently in people.
Our meetings were positive, with many government officials expressing a shared concern for the challenges faced by the ALS community and a willingness to take two specific actions: joining the all-party ALS Caucus and writing a letter to the Minister of Health in support of the asks. Thanks to all who took part in the day for your commitment, time and courage and to the MPs, Senators and staff who met with us.
What you can do:
While the advocacy day meetings helped to kickstart discussions with government following the 2019 federal election, continued outreach and engagement will be essential. We have identified a number of follow-up activities that we will look to begin implementing in the coming weeks once opportunities for engagement are more available. Maintaining our momentum will be important, but must be balanced with the priority response being given to COVID-19 to ensure that our outreach is as effective as possible.
We will continue to provide updates on this blog about ways to advocate for substantial changes to Canada’s drug access pathway and dedicated ALS research funding. Also – keep an eye on our social channels for updates and information. Together we are stronger, and your actions can make a difference.
More Information
In addition to the links provided throughout the above article, these additional information resources provide more background and context about the asks:
While on Parliament Hill, we had more than 25 meetings with MPs, Senators and their staff, including:
MP Darren Fisher, Parliamentary Secretary to Health
MP Ron McKinnon, Chair of the House of Commons Health Committee
MP Matt Jeneroux, Vice-Chair of the House of Commons Health Committee
The office of MP Don Davies, NDP Health Critic
MP Francis Drouin, Chair of the ALS Caucus
Canada continues solidifying its reputation as a leader in ALS research innovation, as evidenced by the magnitude and quality of conversations, knowledge sharing, and relationship building at the 2024 ALS Canada Research Forum. From April 27 to 29, researchers, industry partners, ALS Canada supporters, and more attended the in-person, three-day event, that aimed to move the needle on research toward effective therapies and avenues to improve the quality of life for people affected by ALS.
The weekend kicked off with a keynote presentation by neurologist Prof. Orla Hardiman on PRECISION ALS, a pan-European collaborative platform that brings together researchers, industry experts, and more to accelerate drug discovery and treatment for ALS. Later that evening, attendees heard from community members Mehboob and Sophie Damji. They also learned more about the global work of the International Alliance of ALS/MND Associations from the CEO, Cathy Cummings, and the role ALS Canada plays in working toward a world free of ALS.
Throughout the weekend, attendees were treated to engaging presentations from researchers of all levels, including students, doctoral candidates, postdoctoral fellows, and senior researchers and clinicians. Session topics were diverse – from using virtual reality to improve breathing in people living with ALS, to identifying environmental risk factors for ALS, to poster presentations by up-and-coming junior researchers, to a panel discussion led by seasoned researchers on what makes a great principal investigator. These presentations and conversations further cemented the ALS research community’s deep-rooted commitment to finding a cure for ALS through collaboration and partnership.
For Canadian ALS Learning Institute graduate and ALS Canada Community Ambassador Andrew Dundas, the Research Forum was fascinating and an opportunity to share his lived experiences with researchers. “I’m hoping to understand the research [on] not only for advancement and the cause of ALS, ultimately [to find] a cure, but also for opportunities to improve the quality of life for patients with ALS like myself while a search for a cure is found.”
Andrew reminds us of the reason knowledge-sharing events like the ALS Canada Research Forum are needed – to foster hope, collaboration, and solutions in the pursuit of creating a world free of ALS. He reminds us that finding a cure is not the only goal to strive for and that working towards improving quality of life is just as important.
For Jenny Zhang, a junior researcher at the University of Ottawa and the winner of the Research Forum’s Minute to Win It and poster competitions, the event was a valuable experience that allowed her to network and receive feedback on her work. “As someone currently exploring potential career possibilities, the 2024 ALS Research Forum allowed me to learn more about various ALS research pathways that I wasn’t aware of…All of these experiences will support my progress and improve my work.”
Jenny also echoes the sentiment of many Research Forum attendees that collaboration is critical for advancing ALS research. “I believe that uniting researchers with varying scientific backgrounds and perspectives can help drive innovation and speed up the development of treatments for complex diseases like ALS,” she said. “Bridging together researchers and clinicians and people living with or affected by ALS has provided a sense of hope for the community to continue making progress in ALS research and improve quality of life.”
The 2024 ALS Canada Research Forum is made possible thanks to generous support from our platinum sponsor, Mitsubishi Tanabe Pharma Canada; our gold sponsor, Amylyx Pharmaceuticals; and our silver sponsors, Biogen and QurAlis. We thank our sponsors for their support and generosity in fostering collaboration, knowledge sharing, and capacity building at the 2024 ALS Canada Research.
ALS Society of Canada rallying the community together to bring awareness to nearly 4,000 Canadians living with ALS and their families.
Toronto, Ontario – ALS Awareness Month kicks off June 1, as the ALS Society of Canada (ALS Canada) brings the community together to build recognition of what amyotrophic lateral sclerosis (ALS) is and the impact the relentless disease has on nearly 4,000 Canadians living with the disease and their families.
“An ALS diagnosis can be devastating. What we want people to know is – you are not alone,” says Tammy Moore, CEO, ALS Canada. “ALS Canada’s mission is to work with the ALS community to improve the lives of Canadians affected by ALS through advancing research, care, advocacy, and information. We realize that with each person diagnosed, there are roughly six additional people we touch within their circle of care. It’s important that we’re here, united together in our support. At ALS Canada, we do this by empowering people living with ALS to navigate the current realities of the disease, be informed consumers of ALS information, and advocate effectively for change. We also invest in high-quality research, that will fuel scientific discovery and hopefully lead to more approved therapies and improved quality of life.”
ALS is a neuromuscular disease that progressively paralyzes people because the brain can no longer communicate with the muscles of the body that we are typically able to move at will. As a result, people with ALS often face a swift decline in the ability to talk, walk, eat, swallow, and eventually breathe. There is currently no cure for the disease that carries a lifetime risk of 1 in 300 for each of us. In addition to advancing research, care, advocacy and information, ALS Canada provides community-based services, including direct support provided by the ALS Canada Equipment Program and ALS Canada Community Leads to Ontario families living with ALS.
This June, help us recognize ALS Awareness Month by getting involved with ALS Canada in a variety of ways:
Purple for Awareness. Keep your eyes open for lighting and illuminations of local landmarks in your area as they go purple to recognize this important month. Check out the CN Tower, Nathan Phillips Square, and Niagara Falls throughout June. Take action! Snap a picture and post on your social media channels and tag @ALSCanada to show your support.
Lou Gehrig Day. Tune in on June 2 as Major League Baseball (MLB) recognizes Lou Gehrig Day, honouring the baseball great for his legacy and the awareness created for ALS around the world. The Blue Jays will mark the day at their home game.
Global ALS Awareness Day. On Global ALS Awareness Day (June 21), ALS Canada will host a live webinar featuring the Chairs of the Canadian ALS Research Network (CALS) and provide an overview of the Top 10 exciting things about our understanding of ALS in 2024 presented by Dr. David Taylor, Vice-President, Research and Strategic Partnerships, ALS Canada. Register for free.
Get Walk Ready! Get connected with the ALS community by joining the ALS Canada Walk to End ALS; for a complete list of dates and locations, visit walktoendals.ca.
Become a Monthly Donor. During the month of June, sign up for our Circle of Hope Monthly Giving Program and your monthly gift will be matched for three months thanks to our generous matching donor. Sign up today!
Share your story and stay connected. Whether you want to share your journey or keep a loved one’s memory alive, we encourage you to follow ALS Canada on social media at @ALSCanada on Facebook, Twitter, and Instagram. Let us know what #aWorldFreeOfALS means to you.
About ALS and the ALS Society of Canada
Amyotrophic lateral sclerosis (ALS) is an unrelenting and currently terminal disease. It progressively paralyzes people because the brain is no longer able to communicate with the muscles of the body that we are typically able to move at will. Over time, as the muscles of the body break down, someone living with ALS will lose the ability to walk, talk, eat, swallow, and eventually breathe. Nearly 4,000 Canadians live with ALS and approximately 1,000 Canadians are diagnosed each year. Four out of five people living with ALS will die within two to five years of their diagnosis.
The ALS Society of Canada is working to change what it means to live with ALS. Grounded in and informed by the Canadian ALS community, we respond to the urgent unmet need for life-changing treatments by investing in high-quality research that will fuel scientific discovery and by engaging industry, supporting increased clinical capacity and advocating for equitable, affordable, and timely access to proven therapies.
Responding to the tremendous need for current and credible ALS knowledge, awareness and education, we empower Canadians affected by ALS to navigate the current realities of ALS, be informed consumers of ALS information, and advocate effectively for change. In Ontario, we provide direct community services to help people navigate ALS.
Founded in 1977, we are a registered charity that receives no core government funding – our work is powered by generous donors who share our vision of a future without ALS.
Join the conversation and connect with the ALS community online. Find ALS Canada on Twitter, Instagram, or like our page on Facebook.
For more information
ALS Society of Canada media@als.ca
437-703-5402
Amyotrophic lateral sclerosis (ALS) is a complex disease with varying symptoms and severity for people affected. Due to its heterogeneity, diagnosing the disease can be challenging and finding effective treatments can also be difficult.
Through a collective effort, researchers aim to better understand the genetic causes of ALS, identify biomarkers for early detection, and impact how clinicians can treat the disease.
Participating for future generations
Looking back, Kris Noakes can see how her genetic form of ALS has impacted her family through generations. Living with the disease has meant letting go of parts of her life, including her love for running and reimagining her career.
After Kris recovered from the initial shock of her diagnosis, she turned to her First Nations teachings for guidance. Embracing her feeling of responsibility for the community, she is determined to assist in research, advocacy, and support for people like herself living with ALS.
Kris journeys to Sunnybrook Hospital in Toronto four times a year, where the team looks at the progression of the disease, and she undergoes MRI scans, cognitive and speech testing, and has her blood collected.
“People aren’t necessarily thinking of this at the time of diagnosis,” Kris shares. “It’s half a day that can really have an impact on our lives. It’s a small sacrifice to help lead us to finding a cure for this devastating disease.”
Samples and data are de-identified and will be shared globally for researchers to use for scientific advancement. Kris believes the more her samples are used, the better. She likes the idea of her samples travelling around the world and going to the places she might not have the opportunity to see in her lifetime.
“People can study me any way they want. My life depends on it; how can I not participate? My children’s lives, my cousins. The clock is ticking,” she adds.
Importance of personal engagement
CAPTURE ALS prioritizes the voices of people affected by ALS, their families, friends, and communities. It has an active Participant Partner Advisory Council (PPAC) that advises on research priorities, participant recruitment, and engagement guidelines.
“By including the voices of people living with ALS, the research gains an elevated sense of purpose and urgency,” said Shelagh Genuis, a CAPTURE ALS member who works with the PPAC. “Research projects sometimes fall behind schedule, but for someone living with ALS, every day counts. With their presence on our council, researchers are reminded of the time-sensitive nature of their work and are motivated to prioritize the needs of people affected by the disease.”
Participant engagement has been a priority since the beginning of the initiative. Early consultation with focus groups of people living with ALS and family members informed and shaped the funding application, including study design and CAPTURE ALS’ data sharing plan. Today, their participation ensures that the lived experience is embedded in all the research the team engages in.
Healthy Canadians are also needed in research
The ALS Society of Canada (ALS Canada) is proud to support CAPTURE ALS, and our team is actively participating in it. Carolina Jung, research specialist at ALS Canada, recently participated in the study as a healthy control participant.
“Healthy controls are an important part of any research study,” Carolina shared. “For researchers to obtain reliable and impactful results, they need healthy volunteers to participate. It’s a small contribution of your time and effort that can ultimately have a huge impact on people living with ALS.”
Join CAPTURE ALS
The team at CAPTURE ALS is seeking people living with ALS, their families, and control participants who can travel to clinics located near Edmonton, Toronto, Montreal, or Quebec City. To learn more about getting involved, visit captureals.ca.
In Canada, what the provincial health care systems provide does not always match the needs of people living with ALS. This statement rings true for Ontario,where the current ALS care and support landscape in the province presents people living with ALS with significant challengesthat demand immediate action.
The Issue
The impact of an ALS diagnosis onthe person living with the disease and their family, caregivers, and community is tremendous and pervasive – physically, psychologically, and financially. In Ontario, more than1,300 people living with ALS not only face the harsh realities of this disease daily but also a health care system that fails to meet their complex and progressive needs, leaving them without adequate care and support.
Our Solution
To address this urgent issue, the ALS Society of Canada (ALS Canada), in collaboration with the five regional multi-disciplinary ALS Clinics in Ontario (Hamilton, Kingston, London, Ottawa, Toronto), developed the Ontario Provincial ALS Program.
The Ontario Provincial ALS Program is a comprehensive solution that addresses the complex, critical needs of the ALS community. The program includes four key recommendations:
Recommendation 1: Address the disparities in access to multi-disciplinary ALS Care
Issue: Due to the complex nature of ALS, people living with the disease have substantial care and equipment needs that evolve and increase over time. Effective management of ALS requires access to multi-disciplinary ALS clinics where health care providers, such as speech language pathologists, dietitians, social workers, respiratory therapists, and occupational therapists, play a key role in optimizing care. However, Ontario’s five regional ALS clinics are beyond capacity, under-resourced and unable to meet the unique levels of careidentified in the Canadian Best Practice Recommendations for the Management of ALS.
Solution: The Ontario government to provide incremental investments to ALS clinics to standardize and enhance existing care models, optimizing ALS care and ensuring each person living with ALS in the province receives the highest quality care.
Recommendation 2: Improve the quality of life and help people living with ALS maintain their independence, dignity, and safety
Issue: ALS is an incredibly isolating disease due to the lack of awareness and the increasingly difficult physical realities. To support a person living with ALS, their caregiver, and the people closest to them, they are connected toALS Canada Community Leads located throughout Ontario. ALS Canada Community Leads provide direct, in-home support and individualized information and resource navigation to ensure people are well-supported, helping to augment the healthcare system.
As a person living with ALS progresses in their disease, so does their reliance on mobility and communication equipment and other assistive devices that help them maintain their independence, dignity, and safety.However, Ontario’s medical equipment programs do not meet the needs of people living with ALS as they are left with equipment for short-term use only or with devices that are outdated for their needs or not right for them, which can put both themselves and their caregivers or families at significant risk. In the end, people living with ALS and their caregivers must turn to ALS Canada, a donor–funded organization, to fill the significant gaps that exist in Ontario’s health care system.
Solution: The Ontario government to allocate funds to ALS Canada’s Community Services and Equipment Programs, ensuring people have access to the right equipment and assistive devices at the right time, improving quality of life and helping people living with ALS maintain independence, dignity, and safety for themselves and their caregivers.
Recommendation 3: Provide coordinated oversight of ALS care
Issue:The lack of comprehensive oversight and coordination for ALS care in Ontariohinders the province’s ability to gather critical patient information, which would inform evidence-based decisions to shape a health care system that meets the needs of the ALS community. Comprehensive data capture, knowledge dissemination, and system planning are essential for a coordinated approach to ALS care.
Solution:Formation of a secretariat to oversee and coordinate ALS care andfacilitate comprehensive data capture, efficient knowledge dissemination, and strategic system planning.
Recommendation 4: Ensure equitable ALS care in northern and rural Ontario
Issue:Many Ontarians living in northern and rural regions face unique challenges in health care access due to vast distances and limited health care infrastructure. This is the case for people living with ALS in northern and rural Ontario, as they must endure long journeys to attend appointments at one of the five ALS clinics located in Toronto, London, Hamilton, Kingston, and Ottawa, leading to disparities and barriers in access to care.
Solution: The development of a regional strategy to provide equitable and accessible ALS care in northern and rural Ontario ensures that people living with ALS receive timely care regardless of their geographic location.
Our Advocacy Progress Highlights
Shortly after submittingtheproposal to the Ontario Ministry of Health in June 2023, ALS Canada began advocating for the implementation of the Ontario Provincial ALS Program.
Government Meetings:Over the past several months, ALS Canada, along with community members, met with Ontario MPPs to discuss the implementation of the Ontario Provincial ALS Program, including the Minister of Health, Sylvia Jones, and the office of the Premier, Doug Ford. We will continue engaging with provincial elected officials, ministers, and other stakeholders to bring forward the realities of Ontarians living with ALS and the critical need for access to urgent care and support they require.
2024 Ontario Pre-Budget Submission: ALS Canada submitted awritten submissionas part of Ontario’s 2024 Budget Consultations, urging the government to invest $6.6 million to implement the recommendations outlined in the Ontario Provincial ALS Program.
2024 Ontario Pre-Budget Consultations: ALS Canada participated in six pre-budget public hearings held across Ontario by The Standing Committee on Finance and Economic Affairs (SCFEA) and local MPPs.
Queen’s Park Advocacy Day:On February 21, 2024, ALS Canada, joined by ALS community members, will host an advocacy day at Queen’s Park,where we will engage with MPPs, urging them to include the Ontario Provincial ALS Program as part of Budget 2024. Keep an eyeon our social media channels for further updates and information on our Queen’s Park Advocacy Day.
What you can do right now
Reach out to your elected official in Ontario, urging them to support the implementation of the Ontario Provincial ALS Program. To inform and empower your advocacy efforts, we have developed resources you can use to approach your MPP.
"*" indicates required fields
Next Steps & Updates
March 26, 2024 – Ontario’s 2024 Budget announcement, did not explicitly include a $6.6 million investment to implement the recommendations outlined in the Ontario Provincial ALS Program. We will continue our discussions with the government and relevant ministries to seek clarification.
We will continue providing relevant updates and ways to advocate on this blog post and our social media channels.
As we bid farewell to 2023, we want to take a moment to celebrate YOU. Your dedication throughout this month, and indeed the entire year, has been nothing short of inspirational. As a community, you have rallied together to show your generosity. And your giving spirit has not only uplifted the ALS community but has also propelled our mission forward.
As we embrace the possibilities of the upcoming year, we have a timely and essential reminder: The end-of-year CRA tax receipt deadline is mere days away!
Why is this momentous for you?
Immediate Impact: Your gift ensures we can continue to support Canadians affected by ALS, helping them today and striving for a future without ALS.
Tax Benefits: For many, the importance of the CRA tax receipt might not be immediately evident. By donating before midnight on December 31, you’re also positioning yourself for a 2023 tax benefit. It’s an excellent way to make your giving go even further. As an organization, ALS Canada is only able to issue these receipts if we receive your donation before the deadline, so don’t delay!
Act now: Seize this win-win opportunity. Donate before the end of the year and ensure you’re ready to benefit during the upcoming tax season.
Warm wishes for a joyful New Year,
Tammy Moore
Chief Executive Officer
ALS Society of Canada
A letter from Tammy Moore, ALS Canada’s Chief Executive Officer
Let me start by saying thank you.
Thank you for standing beside us throughout the year, driven by our shared vision: a future without ALS. Today, I want to share how much closer we are to turning this vision into a reality – and why we need your continued support to get us even closer.
First, let me express my immense gratitude to our entire donor community. Thanks to your support, we’ve made huge strides:
Earlier Diagnoses: With projects like ReferALS, we’re paving the way for faster ALS diagnosis in Canada. This means timely access to treatments, clinical trials, and improved quality of life.
Empowering Our Community: The ALS Canada Canadian ALS Learning Institute (CALI) has become a wealth of knowledge for countless Canadians, providing rich information and empowering them to share their stories and make change.
A Milestone in Treatment: The approval of therapies is a testament to our relentless drive. With your help, we strive to ensure equitable access to treatment options for Canadians.
But our work isn’t finished yet
Nearly 4,000 Canadians are battling ALS daily. They rely on our services, information resources, and support groups to navigate this journey. They rely on our relentless advocacy for access to better treatment options, and they rely on our neverending drive to invest in groundbreaking research. With zero government funding, our lifeline is the collective strength and compassion of donors like you.
Reinforces our pursuit of timely, affordable, and equitable access to therapies.
Continues the critical research funding across Canada, moving us closer to more treatment options for ALS.
Ignites impactful conversations with key government officials, emphasizing the urgency for research funding and policy shifts.
And ultimately, it gets us another step closer to a future without ALS.
This December, let’s rally around families facing ALS. Your donation will make a difference in their lives today and fuel hope, pushing us closer to a world free of ALS.
Your generosity is also a vital reminder to people living with ALS right now that there is still so much they can do and that the ALS community is standing by their side.
Together, ALS Canada is able to be a beacon of hope for thousands of Canadians. Let’s shine brighter this December. The year may be coming to an end, but there’s so much we can still do. Together, let’s create a future without ALS.
With heartfelt gratitude,
Tammy Moore
Chief Executive Officer
Double your impact this GivingTuesday
When it comes to fundraising for ALS, next Tuesday (November 28) is the single most important day of the year, and to help us celebrate the day, we have an exciting announcement. Does this sound intriguing? Keep reading….
Every year, GivingTuesday gains more momentum in Canada as charities across the country rally alongside their donor communities to fund life-changing work. It’s a day for us to come together and support the causes closest to our hearts.
To help make the day a success, The Citrine Foundation of Canada has agreed to double every GivingTuesday donation you make, up to $45,000!
Throughout the day, we will be sending email reminders, plus stories from our community members that will remind you how much your donation truly helps real families across the country. If you’re not subscribed to receive emails from ALS Canada, you can do so here. Make sure you’re signed up so you don’t miss out next week.
On World Science Day, the latest ALS Canada-Brain Canada research awards, with support from Fondation Vincent Bourque, highlight the importance of funding early-career researchers and clinicians
Toronto — In recognition of World Science Day, together with Brain Canada, the ALS Society of Canada (ALS Canada) is pleased to announce the 2023 ALS Canada-Brain Canada Clinical Research Fellowship and Trainee Award recipients. These early career grants are designed to support the training and research of clinicians in clinical care and PhD students and postdoctoral fellows engaged in research related to amyotrophic lateral sclerosis (ALS) across Canada.
With an estimated 3,000 Canadians living with ALS, investing in the next generation of researchers is critical to learning more about the disease, improving therapies, and eventually finding a cure.
“Our commitment to invest in clinicians and researchers early in their careers through the Clinical Research Fellowship and Trainee Award programs ensures that we have top medical and scientific talent working hard to find treatments for people living with ALS,” said Dr. David Taylor, Vice-President of Research and Strategic Partnerships, ALS Canada. “These are critical parts of our national Research Program that drive optimal care and discovery toward our vision of a future without ALS.”
“Investing in the future of ALS research means investing in the brilliant young minds who possess the insights needed to unravel the complexities of the disease,” says Dr. Viviane Poupon, President and CEO of Brain Canada. “Through the Clinical Fellowship Award and the Trainee Award program, Brain Canada proudly supports these up-and-coming scientists, as they are shaping a more hopeful future for those battling ALS.”
The Clinical Research Fellowship is designed to support a clinician’s training in clinical care and research skills related to ALS, which is crucial to building better clinical infrastructure across Canada.
The Clinical Research Fellowship will provide $200,000 in funding.
Summary of 2023 Clinical Research Fellowship
Can we better understand the experience of younger middle-aged adults with ALS to help guide age-appropriate management of the disease? Dr. Andrea Parks, co-supervised by Dr. Agessandro Abrahao, Dr. Lesley Gotlib Conn, Dr. Joanna Sale, and Dr. Lorne Zinman, Sunnybrook Health Sciences Centre, awarded $200,000
The Trainee Awards include two streams of funding: Doctoral students and postdoctoral fellows receive financial support to cover their salaries for up to three years, providing Canadian labs with the necessary funds to have top researchers working on the best projects to better understand the disease and drive toward new treatments for individuals living with ALS.
A total of $303,000 was awarded through the 2023 Trainee Awards.
Summary of 2023 Doctoral Awards
Will this novel decision aid improve early care planning and symptom management in those experiencing bulbar ALS symptoms? Anna Huynh, a PhD student in Dr. Yana Yunusova’s lab at Sunnybrook Research Institute, awarded $50,000 over two years
Do acute viral infections play a role in triggering onset or accelerating the progression of ALS?
Art Marzok, a PhD student in Dr. Matthew Miller’s lab at McMaster University, awarded $25,000 for one year
Can this sophisticated method to measure brain activity help researchers better understand the role of hyperexcitability in ALS and its connection to symptoms? Liane Phung, a PhD student co-supervised by Dr. Agessandro Abrahao and Dr. Lorne Zinman at Sunnybrook Research Institute, awarded $75,000 over three years
Can a better understanding of how this particular protein influences overall protein production in cells offer insights into treating ALS? Amrita Verma, a PhD student in Dr. Neil Cashman’s lab at the University of British Columbia, awarded $75,000 over three years
Summary of 2023 Postdoctoral Fellowship
Can a combination of advanced brain imaging and artificial intelligence uncover a biomarker to better track disease progression? Dr. Isabelle Lajoie, a postdoctoral fellow in Dr. Mahsa Dadar’s lab at the Douglas Hospital Research Centre, McGill University, awarded $78,000 over two years
World Science Day reminds us of the impact science has in all our lives. ALS Canada is proud to support emerging scientists and clinicians whose ideas and discoveries will advance treatment and eventually lead to a world free of ALS.
Funding for Anna Huynh’s Doctoral Award was made possible through partnership with Fondation Vincent Bourque, who generously contributed $25,000 to ALS Canada, which was matched by Brain Canada through the Canada Brain Research Fund (CBRF).
The CBRF is an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada Foundation, which increases Canadians’ support for brain research and expands the philanthropic space for funding brain research to achieve maximum impact. To date, Health Canada has invested more than $145 million in brain research through the CBRF which has been matched by Brain Canada Foundation and its donors and partners.
About ALS Canada and the ALS Canada Research Program
The ALS Society of Canada (ALS Canada) is working to change what it means to live with amyotrophic lateral sclerosis, an unrelenting and currently terminal disease.
Grounded in and informed by the Canadian ALS community, we respond to the urgent unmet need for life-changing treatments by investing in high-quality research that will fuel scientific discovery and by engaging industry, supporting increased clinical capacity and advocating for equitable, affordable, and timely access to proven therapies.
Responding to the tremendous need for current and credible ALS knowledge, awareness, and education, we empower Canadians affected by ALS to navigate the current realities of ALS, be informed consumers of ALS information, and advocate effectively for change.
Through the ALS Canada Research Program, we fund peer-reviewed research grants, foster collaboration and build capacity within Canada’s ALS research and clinical community, and invest in new areas of research positioned to have high impact. As the only national dedicated source of funding for ALS research across Canada, the ALS Canada Research Program aims to accelerate research impact by providing funding for the most promising ALS projects focused on translating scientific discoveries into treatments for ALS. We are grateful for the support of our donors and the contributions from participating provincial ALS Societies through the Walk to End ALS.
About Brain Canada
Brain Canada is a national non-profit organization that enables and supports excellent, innovative, paradigm-changing brain research in Canada. It plays a unique and invaluable role as the national convener of the brain research community. We join people, labs and platforms across the country, as well as institutions, organizations and sectors – to drive innovation and foster an interconnected brain research system. Our work enables Canada to excel and make even greater contributions to the global quest to understand the brain and brain disorders. Join us in funding brilliance daily, braincanada.ca.
About Fondation Vincent Bourque
Vincent was diagnosed with ALS in 2015. He knew that ALS was not an incurable disease, but an underfunded one. With his wife, Isabelle Lessard, and many friends, he created a Fondation to help families living with ALS and to support research in order to eradicate ALS. He passed away in 2018, but his legacy to the ALS community is immeasurable. The Fondation Vincent Bourque has raised more than $1,200, 000 since 2018, given five research grants to star researchers dedicated to ALS, and distributed more than $250, 000 to help families. The Fondation Vincent Bourque is proud to be working with ALS Canada and Brain Canada toward a future without ALS.
-30-
Join the conversation and connect with the ALS community online. Find ALS Canada on Twitter, Instagram, or like our page on Facebook. Visit als.ca to find out more.
For more information ALS Society of Canada media@als.ca
437-703-5402
After finishing his PhD in France, Dr. Ghazale moved to Canada to work with Dr. Carol Schuurmans at Sunnybrook Research Institute. Her team examines if neuronal reprogramming could serve as a potential treatment strategy for neurodegenerative diseases, including ALS.
ALS causes damage to neurons, affecting the body’s everyday ability to function. Dr. Ghazale’s work focuses on attempting to reprogram glial cells – a common and abundant type of brain cell – into new neurons. The team hopes these fresh cells could effectively integrate with existing cells in brains of people with ALS, improving their capacity and quality of life.
At the moment, Dr. Ghazale is testing the strategy in animal models. But with this influx of funding, he notes he can speed up his project timeline and do higher-tech experiments. The award will also help him refine his strategy to potentially translate this work to clinical applications.
“I know that this work could one day end up supporting people living with ALS and their families and help … ease what they’re going through,” he says. “This is what motivates me every day to keep working hard to improve therapeutic strategies.”
“We must continue to push the boundaries of ALS research,” says Dr. Viviane Poupon, President and CEO of Brain Canada. “It’s through these uncharted territories that we will uncover the solutions and enable ourselves to envision a future where ALS no longer exists.”
Funding for the 2022 Postdoctoral Fellowship was made possible by Fondation Vincent Bourque, who generously contributed $82,500 to ALS Canada, which was matched by Brain Canada through the Canada Brain Research Fund (CBRF).
The CBRF is an innovative arrangement between the Government of Canada (through Health Canada) and Brain Canada Foundation, which increases Canadians’ support for brain research and expands the philanthropic space for funding brain research to achieve maximum impact. To date, Health Canada has invested more than $145 million in brain research through the CBRF which has been matched by Brain Canada Foundation and its donors and partners.
The ALS Canada-Brain Canada Trainee Program has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada), Brain Canada Foundation and ALS Canada.
Meet the students who received the 2022 ALS Canada – Brain Canada Doctoral Awards
PhD student Lucia Meng Qi Jadon (previously Liao) is the recipient of a $75,000 ALS Canada – Brain Canada 2022 Trainee Award. She will use the funding to investigate whether a newly discovered tag on TDP-43 might have an important role to play in ALS.
For her first six months of doctoral work in Dr. Dale Martin’s lab at the University of Waterloo, Lucia struggled. “I was trying to show something that hadn’t been shown before, so it was difficult,” she said.
But then – success. She detected a faint signal that confirmed she was on the right path. Thanks to her persistence, her work is opening up a new pathway for research.
In a way, the award was like that first signal, confirming her work as a researcher. “I put in all this work, and this award helps me know I’m good enough to be here,” she said. “It’s a huge encouragement that I am cut out for this.”
Lucia’s desire to understand the intricate, complex processes of human cells drives her passion for research.
“When you discover one process, it immediately opens up new possibilities. It’s like a puzzle you keep finding more pieces to,” she says.
Lucia’s project looks at one piece of the complicated ALS puzzle. Early in her PhD work, she confirmed that TDP-43 undergoes a modification called palmitoylation. This process may play a role in TDP-43 mislocation, one of the most common hallmarks of ALS.
She will use this funding to better define the properties of palmitoylation of TDP-43 and understand how it might be abnormal in ALS.
“I’m peeling back the layers, little by little,” she says.
“Ms. Jadon’s work will serve as a beacon, drawing the attention of like-minded scientists eager to explore new frontiers in ALS research,” says Dr. Viviane Poupon, President and CEO of Brain Canada.
Lucia says looks forward to sharing her findings to spark new collaborations within the ALS research community. “I want to establish the basics of this information I discovered and get this out there,” she said. “Then other researchers will know this is something they may want to look into.”
The ALS Canada-Brain Canada Trainee Program has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada), Brain Canada Foundation and ALS Canada.
Meet the students behind the 2022 ALS Canada – Brain Canada Trainee Awards
Charlotte Manser is the recipient of a $75,000 ALS Canada – Brain Canada 2022 Trainee Award. As a PhD student at the University of Ottawa, she investigates how ALS-linked genes might contribute to the loss of normal stress granule formation.
When our cells are stressed, they create “stress granules” to protect RNA, which are critical substances to cellular health. Charlotte explores how the abnormal accumulation of stress granules might contribute to the mislocation of the protein TDP-43, a common hallmark of ALS.
She has tested many genes that might be linked with both stress granule formation and ALS.
“I found two hits that I’m actively pursuing,” she says. “With these, we can try to uncover new mechanisms of disease or a new therapeutic target. They can help us better understand how the disease comes about.”
Determination motivated by loss
Charlotte’s work is motivated by her personal connection to the disease.
In 2013, her father died from ALS. Around that time, she switched her undergraduate major from forensics to neuroscience.
“It was a light bulb moment,” she says. “I knew this is what I wanted to do.”
She also became an active member of the community of families affected by ALS. Charlotte notes that it means a lot for this same community to recognize her work with this award.
“This work represents the hope of turning something awful, like grief, into something productive and positive,” she says. “My hope is that I can contribute something to the field so that it isn’t so bad for the next person.”
The ALS Canada-Brain Canada Trainee Program has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada), Brain Canada Foundation and ALS Canada.
That’s a wrap! Our September events have come to an end at ALS Canada, and we can’t help but look back at how the community came out to ride and pull to end ALS. Both the ALS Canada Pull to End ALS and ALS Canada Revolution Ride bring us together in unique and challenging ways, demonstrating our commitment to raising awareness, honouring the people we’ve loved and lost, and ultimately helping change the future of ALS.
Pull to End ALS
The Pull to End ALS never fails to make an impact – while the shock of challenging yourself to pull a 42,000-lb transport truck is mighty, the energy everyone brings to the event with the shared goal of a future without ALS is mightier. As teams stepped up to pull, cheered on by friends and family, we were reminded that the weight of the challenge is nothing compared to the weight 3,000 Canadians living with ALS face every day. This year, the Pull to End ALS raised an incredible $189,000 and counting – funds that are critical for research investment, community-based support services, and advocacy initiatives! Check out the event’s energy and reflect on some of our favourite moments of the day by visiting the photo album.
Revolution Ride
The ALS community knows the power we hold together, and at this year’s Revolution Ride, we weren’t afraid to show it! Coming together in picturesque Dundas, Ontario, riders geared up to take on the new 12km route and the familiar 40km and 90km routes – riding to change what it means to receive an ALS diagnosis. You can look back at the magic of the day in our photo album – reflecting on the sunny skies and inspiring energy encompassing the event as we came together to make a difference. With the generous support of our riders, those who donated, and the event volunteer committee, the event was an outstanding success, raising$280,000 and going – all to help in our work to create a future without ALS!
ALS Canada would like to thank everyone who participated and supported the Pull to End ALS and Revolution Ride. This September was a reminder that together, we are stronger as we work toward our shared cause – changing the reality of receiving an ALS diagnosis. Though the year isn’t over yet – stay tuned to our social channels to see what exciting events are happening next!
ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the October 2023 Research Update, you’ll learn about advances in understanding the presymptomatic stage of ALS, new guidelines for genetic testing and counselling, an experimental cell replacement strategy, new insights into cellular pathways disrupted in ALS, and more.
We recently developed a research glossary that contains a list of scientific and medical terms and definitions relevant to ALS. The glossary was created to support knowledge-sharing by helping to provide clarity around terminology that may be unfamiliar to our readers. Click here to download a copy.
Uncovering early blood biomarkers for ALS: A promising step towards timely intervention
Researchers have identified specific blood biomarkers that may signal changes prior to symptom onset in ALS.
Multiple lines of evidence suggest that metabolic alterations occur several years before the onset of ALS symptoms. For example, a previous study showed a consistent reduction in metabolic activity among presymptomatic ALS gene mutation carriers compared to healthy controls.
In this UK-based study, researchers analyzed blood tests obtained during routine health screenings from individuals who later received an ALS diagnosis. Using complex statistical methods, they compared a range of blood markers, including cholesterol levels and triglycerides, with those from a healthy control group. The analysis revealed a pattern: individuals with ALS experienced metabolic changes, specifically a decline in both total cholesterol and low-density lipoprotein cholesterol, well before the onset of symptoms and several years ahead of their formal diagnosis. Notably, in recent years, other research groups have identified altered, but different, metabolic markers prior to symptom onset.
While researchers note that further studies are required to better understand the relevance of these findings at the individual level, the results provide further evidence for the existence of a presymptomatic phase in ALS characterized by metabolic changes. The ultimate goal is to discover a highly sensitive early warning signal for ALS, so that intervention can take place before irreversible motor neuron damage occurs. This work represents an important step in that direction.
With increasing knowledge of the genetic causes of ALS, research centered on the presymptomatic stage has become a prominent area of interest in the field. ALS Canada recently sponsored and participated in a workshop co-hosted by the ALS Hope Foundation and Genetic ALS & FTD: End the Legacy that focused on identifying gaps in knowledge in this area and developing guidelines for the clinical management of individuals genetically at risk for ALS. This shift in thinking, with a strong focus on the presymptomatic phase, is critical to reshaping the way we approach ALS treatment in the years ahead.
Development of genetic testing guidelines for ALS to promote standardized care and support
An expert panel have developed guidelines to support all stakeholders in the ALS community in navigating the benefits and challenges of genetic testing.
Significant strides have been made in unraveling the genetic underpinnings of ALS. Earlier this year, the FDA granted approval for the first targeted genetic therapy, known as tofersen or Qalsody, designed to treat SOD1-linked ALS. Genetic factors have also been shown to play a role in some sporadic (non-inherited) ALS cases. As research and care in this area continue to advance, it’s critical that genetic testing practices keep up with these developments.
In this study, researchers used a systematic approach to develop a set of guidelines to improve and standardize genetic counselling and testing practices among healthcare providers. A total of 35 guideline statements were developed. Briefly, the guidelines recommend that all people living with ALS should be offered genetic testing for, at a minimum, the four most common ALS genes: C9ORF72, SOD1, FUS, and TARDBP. Specific education and risk assessments that should be provided before and after testing are also identified, along with instructions for laboratories conducting the tests.
These evidence-based guidelines will help to ensure that everyone involved in the ALS community better understand the advantages and complexities of genetic testing. With gene-targeted clinical trials ongoing for several other ALS-associated genes, these guidelines are timely and will help to promote fair access to genetic testing and gene-targeted treatments when available (and applicable). In line with the rapid advancements in this area, ALS Canada is working to develop a central hub on our website to provide more comprehensive and centralized information on ALS genetics. Stay tuned for more information.
Advances in a cell replacement strategy to restore neuromuscular function in ALS
Scientists have developed a technique to transplant healthy nerve cells into mice with an aggressive form of ALS.
The neuromuscular junction (NMJ) is a vital connection point where motor neurons, the nerve cells responsible for voluntary muscle movements, communicate with muscle fibers. Many researchers believe that one of the earliest events in ALS is the detachment of motor neurons from muscle fibers at the NMJ.
In this study, researchers set out to develop a strategy to help restore muscle function in ALS. Using a mouse model, healthy motor neurons derived from stem cells were placed near target muscles. The transplanted neurons were able to form connections with nearby muscle cells, however, they were not integrated into the body’s natural neural pathways through the brain and spinal cord. As a result, external activation was required to stimulate these neurons to pass signals to muscle cells, and this is where a technique called optogenetics played an important role. Using this technique, researchers were able to trigger motor neuron activity by shining a specific type of light on the cells.
Initial experiments faced challenges with the immune system attacking the transplanted cells, however, a specific therapy called H57-597 prevented rejection and allowed healthy connections to be made between neurons and muscles. With regular stimulation, researchers found that muscle connections in the mice grew stronger, resulting in more powerful muscle movements and reduced muscle wasting.
Though these findings are interesting, it’s important to note that the research was conducted in mice, and further studies are needed to determine if this approach can be translated to humans. The long-term vision involves the potential use of implantable devices to deliver the required external stimulation for muscle activity. Ultimately, this work offers hope for the development of a novel cell therapy that could potentially benefit people living with ALS in the future.
Insights into the role of NEK1 and its therapeutic potential in ALS
New research uncovers the cellular pathways affected by NEK1 gene mutations in ALS, providing important foundational knowledge for considering NEK1 as a future therapeutic target.
In 2016, an international team of researchers, including Canadian scientists, first identified NEK1 as a gene associated with ALS. Mutations in NEK1 account for 2 to 3% of both familial and sporadic ALS cases. Yet, the mechanisms through which these mutations contribute to motor neuron dysfunction remain unknown.
In this study, researchers utilized motor neurons derived from individuals carrying NEK1 mutations and fruit flies to model the disease. The results showed that NEK1 mutations disrupt two vital cellular pathways: the microtubule cytoskeleton and nucleocytoplasmic transport (NCT). NEK1 mutations were found to interfere with the function of microtubules, which are essential components to maintaining the structural integrity of a cell. Furthermore, these mutations were found to also affect NCT, a process that involves the exchange of substances between two important compartments of the cell – the nucleus and cytoplasm. Both pathways play a critical role in ensuring the cell’s survival and have been implicated in ALS in many other studies.
Specific anticancer medications, like paclitaxel and the experimental treatment laulimalide, are known to halt cell division by stabilizing microtubules. The researchers decided to test the potential of these drugs in the context of ALS and found that these compounds were effective in restoring the deficits linked to NEK1 mutations in both pathways. This suggests a possible connection between the two cellular processes.
It’s important to emphasize that these cancer drugs can be highly toxic, with a lengthy list of side effects, and may not be suitable for ALS treatment. Nevertheless, this study provides valuable insights in the role of NEK1 in ALS and provides proof-of-concept that stabilizing microtubules could hold potential as a therapeutic approach for ALS. Researchers are now working to better understand exactly how NEK1 regulates these pathways in human neurons, which is important to inform future treatment strategies.
New research sheds light on widespread RNA and protein misplacement in ALS
A new study reveals that protein and mRNA mislocalization within ALS-affected motor neurons may be more widespread than previously thought.
In ALS, proteins like TDP-43 often move from their usual location in the cell’s nucleus (the central hub housing DNA) to the cytoplasm (the region outside the nucleus), where they tend to aggregate into clumps and no longer function properly. Recent findings suggest that this misplacement issue is widespread, extending beyond a few proteins and including mRNA molecules, which play an important role in delivering instructions for protein synthesis from DNA located within the nucleus.
In this study, researchers used stem cells derived from ALS patients with mutations in two ALS-linked genes, TARDBP and VCP, to create motor neurons in the lab. They separated the cell into its two primary compartments, the nucleus and the cytoplasm, and analyzed the distribution of both mRNA and protein within each. They discovered that the ALS-affected motor neurons exhibited significant mislocalization of hundreds of mRNAs and proteins compared to healthy cells.
The movement of these mRNAs and proteins between the nucleus and cytoplasm hints at issues with the cell’s internal transport mechanisms. Additionally, the mislocalized mRNAs and proteins tended to interact more with each other compared to their correctly positioned counterparts. This suggests that as these mRNAs and proteins mislocalize, they might inadvertently drag each other along, creating a domino effect within the cell.
In an attempt to restore normal protein and mRNA localization, researchers tested an experimental therapy called ML240, which is designed to block the activity of the VCP enzyme. They found that it partly corrected mislocalization and reduced DNA damage, indicating that VCP inhibition may have therapeutic potential in ALS.
The researchers note that future studies are needed to validate these findings in different ALS genetic backgrounds and models. Regardless, this work represents a shift in our understanding of ALS, revealing that it involves not just the abnormal movement of a handful of proteins, but rather the widespread mislocalization of numerous proteins and mRNAs, opening up new avenues for research and potential treatments.
Note: We have included links to the publications because we know you may be interested in the original source papers. While abstracts are always available, many journals are subscription based, and in some cases, full papers may only be accessed at a cost.
Meet the junior researchers who received the 2022 ALS Canada – Brain Canada Trainee Awards
Donovan McDonald is the recipient of a $75,000 ALS Canada – Brain Canada 2022 Trainee Award. As a PhD student, he investigates how the function of tRNA could contribute to ALS disease processes.
Donovan came to Canada from the Bahamas. “People don’t always recognize the challenges that international students face,” he says. Funding opportunities, for example, can be far more limited.
Award programs like those provided by ALS Canada and Brain Canada help fill a critical funding gap for promising students like Donovan.
“Supporting international students in brain research is vital for fostering diverse perspectives, advancing global scientific collaboration, and accelerating breakthroughs in understanding the complexities of the brain,” says Dr. Viviane Poupon, President and CEO of Brain Canada.
“It’s not just about the money,” Donovan says. “It’s also having your research recognized. This is crucial to your development as a scientist.”
Donovan’s original project sought to understand basic biological processes around tRNA. This critical molecule acts as a master key within cells to help proteins form. But working alongside prominent ALS researchers at Western University, he realized how relevant his work could be to exploring “uncharted territory” in ALS research.
In particular, Donovan is exploring how tRNA dysfunction might contribute to ALS in relation to a protein called angiogenin. Researchers have linked mutations in angiogenin, which helps regulate tRNA, to genetic cases of ALS.
“Despite being known for a long time, very few studies look at angiogenin and its role in ALS. That’s where I come in,” Donovan says.
The young researcher hopes his work helps others recognize to the idea that tRNAs are important molecules to study in ALS.
“I want to unravel how tRNA dysfunction can help point to either development of or predisposition to ALS,” he says. The ALS Canada – Brain Canada Trainee Award will help him do just that.
The ALS Canada-Brain Canada Trainee Program has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada), Brain Canada Foundation and ALS Canada.
Meet Dr. Philip McGoldrick, recipient of the 2022 ALS Canada – Brain Canada Career Transition Award
Dr. Philip McGoldrick, a researcher at the Tanz Centre for Research in Neurodegenerative Diseases at the University of Toronto, is the 2022 recipient of a $250,000 ALS Canada – Brain Canada Career Transition Award.
This award helps launch talented early-career researchers, allowing them to set up their own labs, giving them the independence to establish their own research programs.
“This award enables me to continue something I’ve been passionately working on for several years,” he says. “The work I am doing is so exciting. It would have been a huge loss to not be able to continue it.”
Dr. McGoldrick was inspired to study neurodegenerative disease at a young age after seeing how these types of diseases affected family members. After moving to London (UK) for a PhD, ALS soon caught his interest.
“It was the most interesting one of the diseases being studied,” he says. He’s been working in ALS since 2008.
Dr. McGoldrick studies mutations in the C9ORF72 gene – the most common genetic cause of ALS. His current projects explore how the loss of function that occurs when C9ORF72 is mutated can affect a crucial biological process called nucleocytoplasmic transport. He and his co-researchers recently published an article on the topic in Cell Reports. He is also interested in how these insights could be helpful in understanding sporadic cases of ALS.
“This support will allow me to investigate a fundamental but understudied mechanism that may contribute to ALS,” he says. “My hope is that I can be part of a sustained effort on multiple fronts to understand a genetic cause of ALS, but also apply these findings to understand sporadic disease too.”
“This transformative program and collaboration with ALS Canada has the potential to inspire early-career researchers to explore innovative approaches, which could lead to a future without ALS,” says Dr. Viviane Poupon, President and CEO of Brain Canada.
The ALS Canada-Brain Canada Trainee Program has been made possible by the Canada Brain Research Fund (CBRF), an innovative arrangement between the Government of Canada (through Health Canada), Brain Canada Foundation and ALS Canada.
ALS Canada’s mission is to improve the lives of people affected by ALS through support, advocacy, and investment in research for a future without ALS.
We use cookies and other technologies to understand how you use our site and to improve your experience and provide you with valuable content. By continuing on this website, you consent to the use of these cookies. For more information and to opt-out of cookies, visit the cookie section of our privacy policy.
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.